Skip to main content

Advertisement

SpringerLink
Log in

Is Ki67 Effective as a Prognostic Marker in Node-Positive Breast Cancer Patients?

  • Original Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Ki67 is a proliferation marker commonly assessed by immunohistochemistry in breast cancer, and it has been proposed as a clinical marker for subtype classification, prognosis, and prediction of treatment modalities. Therefore, this study aimed to evaluate the prognostic significance of Ki67 in node-positive breast cancer. A total of 251 cases of axillary lymph node-positive breast cancer were included in the study. Several clinicopathologic factors were collected: age, menopausal status, tumor size, node involvement, tumor grade, estrogen and progesterone receptors, HER2, and Ki67 expression. We analyzed if these parameters could be considered as a prognostic factor. Associations of the Ki67 index with other prognostic factors were evaluated both as continuous and categorical variables. Breast cancer-specific survival analysis of the ki67 level was evaluated with Kaplan–Meier survival curve and Cox regression model adjusted for a known prognostic factor. The majority of patients was alive and without tumor relapse at the moment of the analysis (90.8%). A cutoff of 20% separated tumors into a Ki67-low (n = 94) or Ki67-high group (n = 157). The breast cancer-specific survival was 92. 6% and 89.8% for Ki67-low and Ki67-high groups, respectively. Univariate and multivariate analysis showed that in this lymph node-positive clinical trial, the predictors for breast cancer survival were higher N stage and triple-negative subtype was independent predictors of breast cancer death. Although the Ki67 index is an effective complementary proliferative tool in breast cancers without lymph node involvement in predicting prognosis and survival, our study shows that it is not an effective tool for showing prognosis and survival in node-positive breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Coleman M, Quaresma M, Berrino F, Lutz JM, Angelis R, Capocaccia R et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 9:730–756

    Article  PubMed  Google Scholar 

  2. Sorlie T., Tibshirani R., Parker J., et. al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: pp. 8418–8423.

  3. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800

    Article  CAS  PubMed  Google Scholar 

  4. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287. https://doi.org/10.1200/JCO.2007.14.2364

    Article  CAS  PubMed  Google Scholar 

  5. Daidone MG, Silvestrini R (2001) Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 30:27–35

    Article  Google Scholar 

  6. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki- 67 in early breast cancer. J Clin Oncol. 23:7212–7220

    Article  CAS  PubMed  Google Scholar 

  7. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207–212. https://doi.org/10.1093/jnci/djm289

    Article  CAS  PubMed  Google Scholar 

  8. Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J et al (2016) High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer. Oncologist 21(2):150–155. https://doi.org/10.1634/theoncologist.2015-0312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. J Gerdes, U Schwab, H Lemke, H SteinProduction of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31 (1983), pp. 13-20. https://doi.org/10.1016/S1470-2045(09)70262-1

  10. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, ClarkGM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966 78.

  11. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174e83

    Article  Google Scholar 

  12. Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569e75. https://doi.org/10.1200/JCO.2008.17.0829

    Article  Google Scholar 

  13. de Azambuja E, Cardoso F, de Castro Jr G et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Canc 96:1504e13. https://doi.org/10.1038/sj.bjc.6603756

    Article  CAS  Google Scholar 

  14. Sheri A, Dowsett M (2012) Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann Oncol 23(Suppl 10):1x219e27. https://doi.org/10.1093/annonc/mds307

    Article  Google Scholar 

  15. Nirmala Pathmanathan , Rosemary L Balleine, Upali W JaAgeinghe, Kellie L Bilinski, Pamela J Provan, Karen Byth, A Michael Bilous, Elizabeth L Salisbury, John Boyages. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol. 2014;67(3):222–8. doi: https://doi.org/10.1136/jclinpath-2013-201793. Epub 2014 Jan 8.

  16. Zenzola V, Cabezas-Quintario MA, Arguelles M, Pérez-Fernández E, Izarzugaza Y, Correa A, García-Foncillas J (2018) Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. Clin Transl Oncol 20(11):1448–1454. https://doi.org/10.1007/s12094-018-1877-5 (Epub 2018 Apr 18)

    Article  CAS  PubMed  Google Scholar 

  17. Wang W, Jiayi Wu, Zhang P, Fei X et al (2016) Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget 7(21):31079–31087. https://doi.org/10.18632/oncotarget.9075

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zhu X, Chen Li, Huang B, Wang Y, Ji L, Jiong Wu et al (2020) The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep 10(1):225. https://doi.org/10.1038/s41598-019-57094-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Qi-Xing Tan , Qing-Hong Qin , Wei-Ping Yang , Qin-Guo Mo , Chang-Yuan Wei . Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7(10):6862–70.eCollection 2014.

  20. Gallardo A, Garcia-Valdecasas B, Murata P, Teran R, Lopez L et al (2018) Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. Breast Cancer Res Treat 167(1):31–37. https://doi.org/10.1007/s10549-017-4486-z (Epub 2017 Sep 1)

    Article  CAS  PubMed  Google Scholar 

  21. Pérez-López ME, García-Gómez J, Alves MT, Paradela A, García-Mata J, García-Caballero T (2016) Ki-67 is a prognostic marker for hormone receptor positive tumors. Clin Transl Oncol 18(10):996–1002. https://doi.org/10.1007/s12094-015-1472-y (Epub 2016 Jan 7)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D et al (2012) How reliable is Ki-67 immunohistochemistry in grade2 breast carcinomas? A QA study of the Swiss working group ofbreast-and gynecopathologists. PLoS ONE 7:e37379. https://doi.org/10.1371/journal.pone.0037379

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC et al (2013) An international Ki67reproducibility study. J Natl Cancer Inst 105:1897–1906. https://doi.org/10.1093/jnci/djt306

    Article  PubMed  PubMed Central  Google Scholar 

  24. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thu¨rlimann B, Senn HJ, (2011) Strategies for subtypes—dealing with thediversity of breast cancer: highlights of the St. Gallen InternationalExpert Consensus on the Primary Therapy of Early BreastCancer 2011. Ann Oncol 22:1736–1747. https://doi.org/10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cheang MC, Chia SK, Voduc D, Gao D, Leung S et al (2009) Ki67 index, HER2 status, and prognosis ofpatients with luminal B breast cancer. J Natl Cancer Inst 101:736–750. https://doi.org/10.1093/jnci/djp082

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-GebhartM, Thu¨rlimann B, Senn HJ, (2013) Personalizing the treatment of women with early breast cancer: highlights of the St GallenInternational Expert Consensus on the Primary Therapy of EarlyBreast Cancer. Ann Oncol 24:2206–2223. https://doi.org/10.1093/annonc/mdt303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Subik K., Lee J.-F., Baxter L., Strzepek T., Costello D., Crowley P. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Canc. Basic Clin. Res. 2010; 4 117822341000400004.

  28. Mohammed AA (2019) Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study. Ann Med Surg (Lond) 48:129–134. https://doi.org/10.1016/j.amsu.2019.11.005

    Article  Google Scholar 

  29. Young-Joon Kang, Han-Byoel Lee, Yun Gyoung Kim, JaiHong Han, Yumi Kim et al. Ki-67 expression is a significant prognostic factor only when progesterone receptor expression is low in estrogen receptor-positive and HER2-negative early breast cancer. J Oncol. 2019; 2019: 7386734. Published online 2019. https://doi.org/10.1155/2019/7386734

Download references

Author information

Authors and Affiliations

  1. Dept. of Surgery, Division of Oncological Surgery, Mersin University Medical Faculty, Ciftlikkoy Kampusu, 33343, Yenişehir, Mersin, Turkey

    Sami Benli

  2. Dept. of Surgery, Division of Breast Surgery, 9 Eylul University Medical Faculty, İzmir, Turkey

    Süleyman Özkan Aksoy & Ali İbrahim Sevinç

  3. Dept. of Pathology, 9 Eylul University Medical Faculty, İzmir, Turkey

    Merih Güray Durak

  4. Dept. of Public Health, Division of Epidemiology, Ankara University Medical Faculty, Ankara, Turkey

    Caner Baysan

Authors
  1. Sami Benli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Süleyman Özkan Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali İbrahim Sevinç
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Merih Güray Durak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Caner Baysan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sami Benli.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benli, S., Aksoy, S.Ö., Sevinç, A.İ. et al. Is Ki67 Effective as a Prognostic Marker in Node-Positive Breast Cancer Patients?. Indian J Surg 84 (Suppl 3), 689–696 (2022). https://doi.org/10.1007/s12262-021-03199-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-021-03199-x

Keywords

Search

Navigation